Health News

NEW YORK--(BUSINESS WIRE)--Veracity Launches Metabolic Power Protein: A Smarter Protein Designed to Strengthen Your Metabolism Without Toxicity....

TEMPE, Ariz.--(BUSINESS WIRE)--Align Technology, Inc. (NASDAQ: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced a new initiative with the Canadian Foundation for the Advancement of Orthodontics (CFAO). Under this initiative, Align has committed to support Invisalign treatment for 30 eligible pati...

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar’s Nasal Vaccine Delivery Solutions Featured in CastleVax Phase II Clinical Trial of an Intranasal COVID-19 Vaccine Candidate...

SAN DIEGO--(BUSINESS WIRE)--Allele Biotechnology & Pharmaceuticals, Inc. (Allele), a San Diego-based technology development and cell manufacturing company, today announced its participation in an up to $25.8 million research project with the University of California, San Diego, funded by the Advanced Research Projects Agency for Health (ARPA-H). The project’s goal is to develop a fully functional, patient-specific, 3D bioprinted liver for transplantation. This project is under ARPA-H’s Pers...

GAINESVILLE, Fla.--(BUSINESS WIRE)--Orthopedic Care Partners (OCP) welcomes Rob Passaro as Vice President of Business Development. His appointment supports OCP’s ongoing growth initiatives, strengthens its market presence, and contributes to building long-term value with physician partners. Passaro brings nearly twenty years of healthcare and business development expertise, having held leadership roles within high-growth, physician-led, and private equity-backed organizations. His experience in...

ATLANTA--(BUSINESS WIRE)--Guardian Pharmacy Services (NYSE: GRDN), one of the nation’s leading long-term care (“LTC”) pharmacy services companies, is reiterating its previously announced 2025 guidance and providing its preliminary financial outlook for 2026. The Company expects to continue its low double-digit adjusted EBITDA growth trajectory in 2026, supported by the strength of its operating model and increased visibility into the year ahead, including anticipated drug pricing changes. The C...

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced its preliminary, unaudited net sales for the fourth quarter and full year ended December 31, 2025, and reaffirmed its full year 2026 revenue guidance. Preliminary and unaudited total net sales for the fourth quarter of 2025 are expected to be approximately $14...

ZHUZHOU, China & BOSTON--(BUSINESS WIRE)--Zonsen PepLib Biotech Inc. (“PepLib”) today announced that it has entered into a worldwide license agreement with Novartis for an undisclosed peptide-based asset in the field of radioligand therapies (RLTs). Under the agreement, Novartis has obtained an exclusive worldwide license and will be responsible for the development and commercialization activities for the asset. The asset has been developed internally by PepLib to date. Through this transaction...

DUBLIN--(BUSINESS WIRE)--The "CD22 Targeted Therapies Market, Approved Drug Sales, Technology Platforms & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering. Report Findings & Highlights: Current & Future Global Market Outlook Insight on CD22 Targeted Approaches Approved Drug Dosage, Price & Sales Insight CD22 Targeted Therapies Development Trends by Region & Indications CD22 Targeted Therapies in Clinical Trials: > 20 Therapies CD22...

BOUNTIFUL, Utah--(BUSINESS WIRE)--Vy Spine, a spine innovation leader using differentiated materials and designs, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its VyBrate VBR System which is designed for use in both the cervical and thoracolumbar spine for vertebral body replacement surgery. The VyBrate VBR is an innovative device combining the osseointegration properties of the OXPEKK material and the novel OsteoVy lattice structure...